JP2018524311A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018524311A5 JP2018524311A5 JP2017565114A JP2017565114A JP2018524311A5 JP 2018524311 A5 JP2018524311 A5 JP 2018524311A5 JP 2017565114 A JP2017565114 A JP 2017565114A JP 2017565114 A JP2017565114 A JP 2017565114A JP 2018524311 A5 JP2018524311 A5 JP 2018524311A5
- Authority
- JP
- Japan
- Prior art keywords
- tnfα trimer
- compound
- tnfα
- trimer
- tnfr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 76
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 76
- 239000013638 trimer Substances 0.000 claims 73
- 150000001875 compounds Chemical class 0.000 claims 34
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims 32
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims 32
- 239000003112 inhibitor Substances 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 10
- 229940124597 therapeutic agent Drugs 0.000 claims 10
- 239000013078 crystal Substances 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 230000011664 signaling Effects 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 102000002067 Protein Subunits Human genes 0.000 claims 2
- 108010001267 Protein Subunits Proteins 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 230000003040 nociceptive effect Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 230000007704 transition Effects 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 240000005561 Musa balbisiana Species 0.000 claims 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 201000005008 bacterial sepsis Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 238000005094 computer simulation Methods 0.000 claims 1
- 238000012926 crystallographic analysis Methods 0.000 claims 1
- 238000009510 drug design Methods 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 238000000126 in silico method Methods 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 238000002424 x-ray crystallography Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021020352A JP2021109880A (ja) | 2015-06-18 | 2021-02-12 | 治療における使用のための新規のＴＮＦα構造 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1510758.4 | 2015-06-18 | ||
| GBGB1510758.4A GB201510758D0 (en) | 2015-06-18 | 2015-06-18 | Novel TNFa structure for use in therapy |
| PCT/EP2015/074491 WO2016202412A1 (en) | 2015-06-18 | 2015-10-22 | NOVEL TNFα STRUCTURE FOR USE IN THERAPY |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021020352A Division JP2021109880A (ja) | 2015-06-18 | 2021-02-12 | 治療における使用のための新規のＴＮＦα構造 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018524311A JP2018524311A (ja) | 2018-08-30 |
| JP2018524311A5 true JP2018524311A5 (https=) | 2018-11-29 |
| JP7336178B2 JP7336178B2 (ja) | 2023-09-11 |
Family
ID=53784155
Family Applications (12)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017565114A Active JP7336178B2 (ja) | 2015-06-18 | 2015-10-22 | 治療における使用のための新規のＴＮＦα構造 |
| JP2017565173A Active JP6659030B2 (ja) | 2015-06-18 | 2015-10-22 | 作用機構 |
| JP2017565189A Active JP6948954B2 (ja) | 2015-06-18 | 2015-10-22 | 抗体エピトープ |
| JP2017565155A Active JP6781718B2 (ja) | 2015-06-18 | 2015-10-22 | モジュレータアッセイ |
| JP2017565174A Active JP6951256B2 (ja) | 2015-06-18 | 2015-10-22 | 抗体 |
| JP2019154528A Active JP6752344B2 (ja) | 2015-06-18 | 2019-08-27 | 作用機構 |
| JP2020174314A Pending JP2021038222A (ja) | 2015-06-18 | 2020-10-16 | モジュレータアッセイ |
| JP2021020352A Pending JP2021109880A (ja) | 2015-06-18 | 2021-02-12 | 治療における使用のための新規のＴＮＦα構造 |
| JP2021095909A Abandoned JP2021153592A (ja) | 2015-06-18 | 2021-06-08 | 抗体エピトープ |
| JP2021155537A Active JP7159420B2 (ja) | 2015-06-18 | 2021-09-24 | 抗体 |
| JP2023001089A Pending JP2023052250A (ja) | 2015-06-18 | 2023-01-06 | モジュレータアッセイ |
| JP2023046164A Pending JP2023100010A (ja) | 2015-06-18 | 2023-03-23 | 治療における使用のための新規のＴＮＦα構造 |
Family Applications After (11)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017565173A Active JP6659030B2 (ja) | 2015-06-18 | 2015-10-22 | 作用機構 |
| JP2017565189A Active JP6948954B2 (ja) | 2015-06-18 | 2015-10-22 | 抗体エピトープ |
| JP2017565155A Active JP6781718B2 (ja) | 2015-06-18 | 2015-10-22 | モジュレータアッセイ |
| JP2017565174A Active JP6951256B2 (ja) | 2015-06-18 | 2015-10-22 | 抗体 |
| JP2019154528A Active JP6752344B2 (ja) | 2015-06-18 | 2019-08-27 | 作用機構 |
| JP2020174314A Pending JP2021038222A (ja) | 2015-06-18 | 2020-10-16 | モジュレータアッセイ |
| JP2021020352A Pending JP2021109880A (ja) | 2015-06-18 | 2021-02-12 | 治療における使用のための新規のＴＮＦα構造 |
| JP2021095909A Abandoned JP2021153592A (ja) | 2015-06-18 | 2021-06-08 | 抗体エピトープ |
| JP2021155537A Active JP7159420B2 (ja) | 2015-06-18 | 2021-09-24 | 抗体 |
| JP2023001089A Pending JP2023052250A (ja) | 2015-06-18 | 2023-01-06 | モジュレータアッセイ |
| JP2023046164A Pending JP2023100010A (ja) | 2015-06-18 | 2023-03-23 | 治療における使用のための新規のＴＮＦα構造 |
Country Status (16)
| Country | Link |
|---|---|
| US (12) | US10775385B2 (https=) |
| EP (8) | EP3311171B1 (https=) |
| JP (12) | JP7336178B2 (https=) |
| KR (2) | KR102599907B1 (https=) |
| CN (6) | CN108055865B (https=) |
| AU (2) | AU2015398984B2 (https=) |
| CA (4) | CA2987823C (https=) |
| CL (2) | CL2017003189A1 (https=) |
| EA (4) | EA201890081A1 (https=) |
| ES (5) | ES2895552T3 (https=) |
| GB (1) | GB201510758D0 (https=) |
| IL (2) | IL256099B2 (https=) |
| MX (2) | MX2017015757A (https=) |
| PL (4) | PL3311170T3 (https=) |
| PT (4) | PT3311168T (https=) |
| WO (5) | WO2016202414A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| CA3255406A1 (en) | 2015-03-31 | 2025-07-03 | Sorriso Pharmaceuticals, Inc. | Tnf-alpha binding polypeptides |
| WO2016156468A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptides |
| SG11201706840WA (en) | 2015-03-31 | 2017-09-28 | Vhsquared Ltd | Peptide construct having a protease-cleavable linker |
| US20160304496A1 (en) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Indazolones as modulators of tnf signaling |
| US9879016B2 (en) | 2015-04-17 | 2018-01-30 | Abbvie Inc. | Indazolones as modulators of TNF signaling |
| AR104291A1 (es) | 2015-04-17 | 2017-07-12 | Abbvie Inc | Moduladores tricíclicos de la señalización por tnf |
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
| EP3519438A1 (en) | 2016-09-30 | 2019-08-07 | VHsquared Limited | Compositions |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| AU2018208458B2 (en) * | 2017-01-10 | 2020-07-16 | ETH Zürich | Cell-protective compounds and their use |
| US12559552B2 (en) | 2019-06-21 | 2026-02-24 | Sorriso Pharmaceuticals, Inc. | IL-23 and TNF-alpha binding bi-specific heavy chain polypeptides |
| KR20220063148A (ko) | 2019-06-21 | 2022-05-17 | 소리소 파마슈티컬스 인크. | 조성물 |
| CA3144567A1 (en) | 2019-06-21 | 2020-12-24 | Scott Crowe | Polypeptides |
| JP7561364B2 (ja) * | 2020-04-30 | 2024-10-04 | 国立大学法人東北大学 | 蛍光偏光免疫分析法 |
Family Cites Families (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2647427B2 (ja) | 1987-04-24 | 1997-08-27 | 帝人株式会社 | 被検者の病態の判定のための検出方法、モノクロ−ナル抗体および検出キット |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US4908372A (en) | 1988-10-13 | 1990-03-13 | Merrell Dow Pharmaceuticals Inc. | Antihistaminic piperidinyl benzimidazoles |
| DE3843534A1 (de) | 1988-12-23 | 1990-07-12 | Basf Ag | Neue tnf-polypeptide |
| US6451983B2 (en) | 1989-08-07 | 2002-09-17 | Peptech Limited | Tumor necrosis factor antibodies |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| GB9028123D0 (en) | 1990-12-28 | 1991-02-13 | Erba Carlo Spa | Monoclonal antibodies against human tumor necrosis factor alpha |
| ATE414768T1 (de) | 1991-04-10 | 2008-12-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| IT1249708B (it) | 1991-09-23 | 1995-03-09 | Tecnogen Scpa | Metodo per la determinazione del fattore di necrosi tumorale (tnf) in forma biologicamente attiva. |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| TW231291B (https=) | 1992-01-09 | 1994-10-01 | Janssen Pharmaceutica Nv | |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5891679A (en) * | 1993-02-03 | 1999-04-06 | N.V. Innogenetics S.A. | TNF-alpha muteins and a process for preparing them |
| CA2119089A1 (en) | 1993-03-29 | 1994-09-30 | David Banner | Tumor necrosis factor muteins |
| WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
| DE69534347T2 (de) | 1994-01-31 | 2006-05-24 | Trustees Of Boston University, Boston | Bibliotheken aus Polyklonalen Antikörpern |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| DE4440613C1 (de) | 1994-11-14 | 1996-07-25 | Leica Ag | Vorrichtung und Verfahren zur Detektion und Demodulation eines intensitätsmodulierten Strahlungsfeldes |
| TW453995B (en) | 1995-12-15 | 2001-09-11 | Novartis Ag | Certain alpha-substituted arylsulfonamido acetohydroxamic acids |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| CN1204230A (zh) | 1997-12-08 | 1999-01-06 | 李建安 | 一种手提电话机用防护罩及其制做方法 |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| GB9828628D0 (en) * | 1998-12-23 | 1999-02-17 | Glaxo Group Ltd | Novel ligand |
| US7101974B2 (en) * | 2000-03-02 | 2006-09-05 | Xencor | TNF-αvariants |
| NZ524980A (en) | 2000-09-01 | 2005-10-28 | Biogen Idec Inc | Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications |
| EP1414810B1 (en) | 2001-06-05 | 2006-08-30 | Boehringer Ingelheim Pharmaceuticals Inc. | 1,4-disubstituted benzo-fused cycloalkyl urea compounds |
| US6632810B2 (en) | 2001-06-29 | 2003-10-14 | Kowa Co., Ltd. | Cyclic diamine compound with condensed-ring groups |
| JP2003040888A (ja) | 2001-07-30 | 2003-02-13 | Sankyo Co Ltd | イミダゾール誘導体 |
| US20060078944A1 (en) | 2002-08-01 | 2006-04-13 | Jun Kuai | Methods and reagents relating to inflammation and apoptosis |
| ES2374068T3 (es) | 2002-12-03 | 2012-02-13 | Ucb Pharma, S.A. | Ensayo para identificar células productoras de anticuerpos. |
| CA2524623A1 (en) | 2003-05-09 | 2004-11-18 | Pharmexa A/S | Immunogenic human tnf alpha analogues with reduced cytotoxicity and methods of their preparation |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| ES2551439T5 (es) | 2003-07-01 | 2018-11-08 | Ucb Biopharma Sprl | Fragmentos Fab de anticuerpos modificados |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| AR045056A1 (es) | 2003-07-15 | 2005-10-12 | Amgen Inc | Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf |
| US7268116B2 (en) | 2003-10-02 | 2007-09-11 | Genhunter Corp. | Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins |
| TW200526780A (en) | 2004-01-06 | 2005-08-16 | Hayashibara Biochem Lab | TNF antagonists and TNF inhibitors comprising the same as the active ingredient |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| US8188223B2 (en) | 2005-05-18 | 2012-05-29 | Ablynx N.V. | Serum albumin binding proteins |
| DE102005023617A1 (de) | 2005-05-21 | 2006-11-23 | Aspre Ag | Verfahren zum Mischen von Farben in einem Display |
| WO2007060411A1 (en) | 2005-11-24 | 2007-05-31 | Ucb Pharma S.A. | Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r |
| TW201531484A (zh) | 2007-05-21 | 2015-08-16 | Alder Biopharmaceuticals Inc | 抗ＴＮＦ-α之抗體及其用途 |
| KR20170036814A (ko) * | 2007-05-21 | 2017-04-03 | 앨더바이오 홀딩스 엘엘씨 | 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체 |
| TW200914052A (en) | 2007-08-03 | 2009-04-01 | Alcon Res Ltd | RNAi-related inhibition of TNFα signaling pathway for treatment of glaucoma |
| EP2535349A1 (en) | 2007-09-26 | 2012-12-19 | UCB Pharma S.A. | Dual specificity antibody fusions |
| US9365644B2 (en) | 2008-04-23 | 2016-06-14 | Epitomics, Inc. | Anti-TNFα antibody |
| KR102050040B1 (ko) | 2008-06-25 | 2019-11-28 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | ＴＮＦα를 저해하는 안정한 가용성 항체 |
| AU2009318779A1 (en) * | 2008-11-20 | 2011-07-07 | Panacea Biotec Ltd | Tumor Necrosis Factor alpha inhibiting peptides and uses thereof |
| JP2010172307A (ja) | 2009-01-30 | 2010-08-12 | Saitama Medical Univ | 関節リウマチに対する可溶性ＴＮＦα／ＬＴαレセプター薬の薬効予測方法、及び薬効予測装置 |
| WO2010118404A2 (en) | 2009-04-09 | 2010-10-14 | California Institute Of Technology | Methods for creating or identifying compounds that bind tumor necrosis factor alpha |
| PE20120835A1 (es) | 2009-04-16 | 2012-07-23 | Abbvie Biotherapeutics Inc | Anticuerpos anti-tnf-alfa y sus usos |
| KR20130010123A (ko) | 2010-04-07 | 2013-01-25 | 아비에 인코포레이티드 | ＴＮＦ-α 결합 단백질 |
| US8377441B2 (en) * | 2010-08-03 | 2013-02-19 | National Cheng Kung University | Treating breast cancer with anti-IL-19 antibody |
| EP2632448B1 (en) | 2010-10-30 | 2020-10-21 | KinDex Pharmaceuticals, Inc. | Cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(-3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives, substantially enantiomerically pure compositions and methods |
| AR084210A1 (es) | 2010-12-08 | 2013-05-02 | Abbott Lab | PROTEINAS DE UNION AL TNF-a |
| WO2012172070A1 (en) | 2011-06-17 | 2012-12-20 | Glaxo Group Limited | Tumour necrosis factor receptor 1 antagonists |
| WO2013024040A2 (en) | 2011-08-12 | 2013-02-21 | B.S.R.C. Alexander Fleming | Tnf superfamily trimerization inhibitors |
| BR112014030940B1 (pt) * | 2012-06-11 | 2022-09-06 | UCB Biopharma SRL | Benzimidazóis que modulam tnf-alfa e composição farmacêutica compreendendo os mesmos |
| EP2867674B1 (en) | 2012-06-28 | 2018-10-10 | UCB Biopharma SPRL | A method for identifying compounds of therapeutic interest |
| CN104619709B (zh) * | 2012-07-13 | 2016-11-09 | Ucb生物制药私人有限公司 | 作为tnf活性调节剂的咪唑并吡啶衍生物 |
| GB201212513D0 (en) * | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
| EP3738605A1 (en) | 2012-09-10 | 2020-11-18 | Xencor, Inc. | Methods of treating neurological diseases |
| JP6134392B2 (ja) | 2013-01-25 | 2017-05-24 | サイモン・エルエルシー | 循環している生物学的に活性な可溶性ｔｎｆの選択的低減用の組成物およびｔｎｆ媒介性疾患を処置する方法 |
| US10173207B2 (en) | 2013-03-12 | 2019-01-08 | Anellotech, Inc. | Regeneration of catalytic fast pyrolysis catalyst |
| US9908944B2 (en) | 2013-07-15 | 2018-03-06 | Novo Nordisk A/S | Antibodies that bind urokinase plasminogen activator |
| GB201321745D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321736D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321749D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321748D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321744D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321741D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321743D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321735D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321732D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321738D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321746D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321742D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| BR112016012243A2 (pt) | 2013-12-09 | 2017-08-08 | Ucb Biopharma Sprl | Derivados de imidazopiridina como moduladores de atividade de tnf |
| GB201321730D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321740D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321733D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321731D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321734D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| ES2750236T3 (es) | 2013-12-09 | 2020-03-25 | UCB Biopharma SRL | Derivados heteroaromáticos bicíclicos condensados como moduladores de la actividad del TNF |
| GB201321737D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321728D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321729D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321739D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| PE20170693A1 (es) | 2014-10-03 | 2017-06-13 | Ucb Biopharma Sprl | Derivados de imidazol pentaciclicos fusionados |
| TWI703156B (zh) | 2015-01-30 | 2020-09-01 | 學校法人埼玉醫科大學 | 抗ａｌｋ２抗體 |
| MX2017011577A (es) | 2015-03-18 | 2017-10-26 | Bristol Myers Squibb Co | Compuestos heterociclicos utiles como inhibidores de factor de necrosis tumoral (tnf). |
| AU2016233288A1 (en) | 2015-03-18 | 2017-11-09 | Bristol-Myers Squibb Company | Substituted tricyclic heterocyclic compounds |
| CA2982446A1 (en) | 2015-03-18 | 2016-09-22 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds useful as inhibitors of tnf |
| US20160304496A1 (en) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Indazolones as modulators of tnf signaling |
| US9879016B2 (en) | 2015-04-17 | 2018-01-30 | Abbvie Inc. | Indazolones as modulators of TNF signaling |
| AR104291A1 (es) | 2015-04-17 | 2017-07-12 | Abbvie Inc | Moduladores tricíclicos de la señalización por tnf |
| GB201509893D0 (en) | 2015-06-08 | 2015-07-22 | Ucb Biopharma Sprl | Therapeutic agents |
| GB201509888D0 (en) | 2015-06-08 | 2015-07-22 | Ucb Biopharma Sprl | Therapeutic agents |
| GB201509885D0 (en) | 2015-06-08 | 2015-07-22 | Ucb Biopharma Sprl | Therapeutic agents |
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| EA033686B1 (ru) | 2015-08-03 | 2019-11-15 | Bristol Myers Squibb Co | Гетероциклические соединения, применимые в качестве модуляторов tnf-альфа |
| KR102679517B1 (ko) | 2015-08-03 | 2024-06-27 | 브리스톨-마이어스 스큅 컴퍼니 | Tnf 알파의 조정제로서 유용한 시클릭 화합물 |
| JP6968092B2 (ja) | 2016-04-01 | 2021-11-17 | ユーシービー バイオファルマ エスアールエル | Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体 |
| JP6968091B2 (ja) | 2016-04-01 | 2021-11-17 | ユーシービー バイオファルマ エスアールエル | Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体 |
| EP3436460B1 (en) | 2016-04-01 | 2021-08-18 | UCB Biopharma SRL | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
| EA201892144A1 (ru) | 2016-04-01 | 2019-04-30 | Юсб Байофарма Спрл | Конденсированные гексациклические производные имидазола в качестве модуляторов активности tnf |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
-
2015
- 2015-06-18 GB GBGB1510758.4A patent/GB201510758D0/en not_active Ceased
- 2015-10-22 MX MX2017015757A patent/MX2017015757A/es unknown
- 2015-10-22 ES ES15784368T patent/ES2895552T3/es active Active
- 2015-10-22 WO PCT/EP2015/074527 patent/WO2016202414A1/en not_active Ceased
- 2015-10-22 EP EP15784370.7A patent/EP3311171B1/en active Active
- 2015-10-22 EP EP21201892.3A patent/EP3988936A1/en not_active Withdrawn
- 2015-10-22 PL PL15784368T patent/PL3311170T3/pl unknown
- 2015-10-22 EA EA201890081A patent/EA201890081A1/ru unknown
- 2015-10-22 WO PCT/EP2015/074490 patent/WO2016202411A1/en not_active Ceased
- 2015-10-22 KR KR1020187001566A patent/KR102599907B1/ko active Active
- 2015-10-22 PL PL15784067.9T patent/PL3311168T3/pl unknown
- 2015-10-22 JP JP2017565114A patent/JP7336178B2/ja active Active
- 2015-10-22 PT PT157840679T patent/PT3311168T/pt unknown
- 2015-10-22 CN CN201580081000.1A patent/CN108055865B/zh active Active
- 2015-10-22 ES ES15784370T patent/ES2902415T3/es active Active
- 2015-10-22 MX MX2017015481A patent/MX2017015481A/es unknown
- 2015-10-22 PL PL15784069T patent/PL3311169T3/pl unknown
- 2015-10-22 JP JP2017565173A patent/JP6659030B2/ja active Active
- 2015-10-22 PT PT157843707T patent/PT3311171T/pt unknown
- 2015-10-22 US US15/736,614 patent/US10775385B2/en active Active
- 2015-10-22 JP JP2017565189A patent/JP6948954B2/ja active Active
- 2015-10-22 EP EP21194582.9A patent/EP3995831A1/en not_active Withdrawn
- 2015-10-22 CA CA2987823A patent/CA2987823C/en active Active
- 2015-10-22 ES ES15784067T patent/ES2948915T3/es active Active
- 2015-10-22 WO PCT/EP2015/074491 patent/WO2016202412A1/en not_active Ceased
- 2015-10-22 US US15/736,558 patent/US11022614B2/en active Active
- 2015-10-22 US US15/736,520 patent/US10705094B2/en active Active
- 2015-10-22 WO PCT/EP2015/074532 patent/WO2016202415A1/en not_active Ceased
- 2015-10-22 EA EA201890080A patent/EA201890080A1/ru unknown
- 2015-10-22 AU AU2015398984A patent/AU2015398984B2/en not_active Ceased
- 2015-10-22 EA EA201890082A patent/EA201890082A1/ru unknown
- 2015-10-22 US US15/736,336 patent/US10883996B2/en active Active
- 2015-10-22 ES ES15784069T patent/ES2895486T3/es active Active
- 2015-10-22 PT PT157840695T patent/PT3311169T/pt unknown
- 2015-10-22 EP EP15784067.9A patent/EP3311168B1/en active Active
- 2015-10-22 CN CN202010405385.5A patent/CN111574517B/zh active Active
- 2015-10-22 KR KR1020187001568A patent/KR20180048571A/ko not_active Withdrawn
- 2015-10-22 CN CN201580081026.6A patent/CN107810419B/zh active Active
- 2015-10-22 JP JP2017565155A patent/JP6781718B2/ja active Active
- 2015-10-22 CA CA2988723A patent/CA2988723A1/en not_active Abandoned
- 2015-10-22 EP EP15784368.1A patent/EP3311170B1/en active Active
- 2015-10-22 CN CN201580080985.6A patent/CN108290945B/zh active Active
- 2015-10-22 PL PL15784370T patent/PL3311171T3/pl unknown
- 2015-10-22 EA EA201890078A patent/EA201890078A1/ru unknown
- 2015-10-22 ES ES15784066T patent/ES2836769T3/es active Active
- 2015-10-22 JP JP2017565174A patent/JP6951256B2/ja active Active
- 2015-10-22 US US15/736,535 patent/US10969393B2/en active Active
- 2015-10-22 EP EP15784069.5A patent/EP3311169B1/en active Active
- 2015-10-22 EP EP21192200.0A patent/EP3960759A1/en active Pending
- 2015-10-22 IL IL256099A patent/IL256099B2/en unknown
- 2015-10-22 PT PT157843681T patent/PT3311170T/pt unknown
- 2015-10-22 CA CA2987827A patent/CA2987827C/en active Active
- 2015-10-22 WO PCT/EP2015/074524 patent/WO2016202413A1/en not_active Ceased
- 2015-10-22 CN CN201580080990.7A patent/CN108139407B/zh active Active
- 2015-10-22 EP EP15784066.1A patent/EP3311167B1/en active Active
- 2015-10-22 CA CA2987698A patent/CA2987698C/en active Active
- 2015-10-22 CN CN201580080984.1A patent/CN107771286B/zh active Active
- 2015-10-22 AU AU2015398985A patent/AU2015398985A1/en not_active Abandoned
-
2017
- 2017-12-04 IL IL256097A patent/IL256097A/en unknown
- 2017-12-13 CL CL2017003189A patent/CL2017003189A1/es unknown
- 2017-12-18 CL CL2017003246A patent/CL2017003246A1/es unknown
-
2019
- 2019-08-27 JP JP2019154528A patent/JP6752344B2/ja active Active
-
2020
- 2020-05-26 US US16/883,859 patent/US11448655B2/en active Active
- 2020-09-04 US US17/013,326 patent/US11674967B2/en active Active
- 2020-10-16 US US17/072,665 patent/US20210140972A1/en not_active Abandoned
- 2020-10-16 JP JP2020174314A patent/JP2021038222A/ja active Pending
-
2021
- 2021-01-07 US US17/143,719 patent/US20210132079A1/en not_active Abandoned
- 2021-02-12 JP JP2021020352A patent/JP2021109880A/ja active Pending
- 2021-05-19 US US17/325,036 patent/US12055549B2/en active Active
- 2021-06-08 JP JP2021095909A patent/JP2021153592A/ja not_active Abandoned
- 2021-09-24 JP JP2021155537A patent/JP7159420B2/ja active Active
-
2022
- 2022-08-30 US US17/823,356 patent/US12474348B2/en active Active
-
2023
- 2023-01-06 JP JP2023001089A patent/JP2023052250A/ja active Pending
- 2023-03-23 JP JP2023046164A patent/JP2023100010A/ja active Pending
-
2024
- 2024-08-28 US US18/818,247 patent/US20250012807A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018524311A5 (https=) | ||
| JP2021109880A5 (https=) | ||
| Zoete et al. | MM–GBSA binding free energy decomposition and T cell receptor engineering | |
| McCoy et al. | Implications of AlphaFold2 for crystallographic phasing by molecular replacement | |
| Christopher et al. | Biophysical fragment screening of the β1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design | |
| US11674967B2 (en) | Method of identifying potential inhibitors of APO TNFα trimers | |
| Wu et al. | Structural basis for oligoclonal T cell recognition of a shared p53 cancer neoantigen | |
| Ren et al. | Hybrid structural model of the complete human ESCRT-0 complex | |
| López-Sagaseta et al. | The molecular basis for Mucosal-Associated Invariant T cell recognition of MR1 proteins | |
| Immormino et al. | Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors | |
| Zhu et al. | Mechanism of NMDA receptor inhibition and activation | |
| Pavlovicz et al. | Efficient consideration of coordinated water molecules improves computational protein-protein and protein-ligand docking discrimination | |
| CA2743361C (en) | Methods and systems for predicting misfolded protein epitopes | |
| Ng et al. | Structural basis for RNA binding and homo-oligomer formation by influenza B virus nucleoprotein | |
| Abayev et al. | The solution structure of monomeric CCL 5 in complex with a doubly sulfated N‐terminal segment of CCR 5 | |
| JP2022033239A (ja) | 操作されたｔｇｆベータ単量体およびｔｇｆベータシグナル伝達のためのそれらの使用 | |
| Li et al. | CACHE Challenge# 1: targeting the WDR domain of LRRK2, a Parkinson’s Disease associated protein | |
| Liu et al. | Structural plasticity of the TDRD3 Tudor domain probed by a fragment screening hit | |
| Wang et al. | Architecture and subunit arrangement of the complete Saccharomyces cerevisiae COMPASS complex | |
| Arannilewa et al. | Molecular docking analysis of Cianidanol fromGinkgo biloba with HER2+ breast cancer target | |
| Zia et al. | Taming the cytokine storm: small molecule inhibitors targeting IL-6/IL-6α receptor | |
| Maurer et al. | Structural basis of the broadly neutralizing anti‐interferon‐α antibody rontalizumab | |
| Chen et al. | Risk factors and mechanisms of immune checkpoint inhibitor-related pneumonitis | |
| Chee et al. | Structure-activity studies of Mdm2/Mdm4-binding stapled peptides comprising non-natural amino acids | |
| Roberts et al. | Mycobacterium tuberculosis chaperonin 10 heptamers self-associate through their biologically active loops |